Please login to the form below

Not currently logged in
Email:
Password:

Servier abandons cancer drug collaboration with Pharmacyclics

Rights to lymphoma treatment abexinostat will be returned

Servier logoServier has ended its collaboration on a prospective new cancer treatment and will return abexinostat's global development and commercialisation rights to Pharmacyclics.

A pan-HDAC inhibitor, abexinostat is currently in phase II clinical trials for B-cell lymphoma and had been thought to have potential in other cancers.

Bob Duggan, chairman and CEO at Pharmacyclics, said: “Now that we have full ownership of the abexinostat asset, we will enter a period of further evaluation to determine its usefulness in oncology.”

A provisional patent application for abexinostat tosylate was filed with the US Patent and Trademark Office in 2013.

Pharmacyclics said it would now evaluate the opportunities that remain with the compound and would provide an update on the programme in mid 2015.

Article by
Kirstie Pickering

29th September 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics